Evaluation of Sofosbuvir and Daclatasvir Combo in COIVD-19 Patients in Egypt

Alexandria University54 enrolled

Overview

Sofosbuvir has been recently recommended as a possible antiviral for COVID-19, based on structural studies and multiple alignment analysis. By comparing the positive-stranded RNA genomes of HCV and SARS-CoV-2, it has been postulated that sofosbuvir might be an optimal nucleotide analogue to repurpose for COVID-19 treatment

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Covid19

Interventions

Sofosbuvir 400 MG/ Daclatasvir 60mgDRUG

Giving these two drugs for treatment of COVID patients

Eligibility

Sex: ALLMin age: 12 YearsMax age: 90 Years

Medical Language ↔ Plain English

Inclusion Criteria: * mild- moderate COVID-19 confirmed by PCR Exclusion Criteria: 1. Patients on renal dialysis 2. Severe COVID-19 cases 3. Patients on amiodarone therapy (given the reported FDA warning of an interaction between amiodarone and sofosbuvir that might lead to severe bradycardia). 4. Children \< 12 years 5. Pregnant and breast feeding women 6. Exacerbation of hepatitis B

Locations (1)

Amr Aly Abd elmoety

Alexandria, Egypt

Outcomes

Primary Outcomes

evaluate the combined effect of Sofosbuvir and Daclatasvir in treatment of patients with mild-moderate Covid-19.

The study assesses the incidence of resolution of symptoms in COVID patients after taking Sofosbuvir and Daclatasvir for 14 days by doing PCR and the result to be negative

Time frame: it is estimated to be 2 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.